All In Biotech

Drug Trial Radar · NCT07916194

A Study of Zovaglutide (ZT002 Injection) in Participants With Hepatic Impairment and Healthy Participants

A Phase I Clinical Study to Evaluate the Pharmacokinetic Characteristics and Safety of Single Dose of Zovaglutide (ZT002 Injection) in Participants With Varying Degrees of Hepatic Impairment and Matched Participants With Normal Hepatic Function

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Nov 13, 2026

Primary completion

Jun 19, 2027

Study completion Sep 25, 2027

Sponsor

Sponsor type
Industry
First posted
Nov 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a single-dose, open-label, non-randomized, parallel design phase I clinical study to evaluate the PK characteristics and safety of single subcutaneous injection of ZT002 Injection in participants with varying degrees of Hepatic Impairment and matched participants with normal hepatic function.

Conditions

  • Overweight, Obesity

Interventions

  • ZovaglutideDrug

    All subjects will be treated with a single subcutaneous injection of Zovaglutide

  • ZovaglutideDrug

    All subjects will be treated with a single subcutaneous injection of Zovaglutide

  • ZovaglutideDrug

    All subjects will be treated with a single subcutaneous injection of Zovaglutide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Concentration Versus Time Curve (AUC) of ZT002 From Time Zero to Infinity (AUC0-∞)Time frame: Start of treatment up to Day 36
  2. Maximum Concentration of ZT002 (Cmax)Time frame: Start of treatment up to Day 36
  3. Area Under the Concentration Versus Time Curve (AUC) of ZT002 From Time Zero to Tlast (AUC0-t)Time frame: Start of treatment up to Day 36

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Henan Infectious Diseases Hospital & The Sixth People's Hospital of Zhengzhou

    Zhengzhou, Henan, China

  • Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.